Radiopharm Theranostics Ltd has released a press release.
Radiopharm receives $4.85M R&D tax incentive
Filed with ASX ·
6ix hasn’t read this filing yet.
Radiopharm Theranostics Limited on 6ix
Earlier from Radiopharm Theranostics
- Entitlement Offer Documents
- Entitlement Offer to raise approximately $10 million
- FDA green light for diagnostic Phase 1 pancreatic trial
- RAD receives approval for Phase 1 therapeutic study of NSCLC
- Appendix 4E and FY23 Financial Report
Later from Radiopharm Theranostics
- Completion of Entitlement Offer
- Phase 1 Therapeutic NSCLC (Lung Cancer) Trial Opens 4 Jan
- 2nd Australian site for Nanomab-PDL-1 Phase 1 trial
- Placement of Entitlement Offer Shortfall
- RAD 502 can halt tumour progression and prolong survival
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics